MeiraGTx UK II Ltd

Quick facts

Phase 2 pipeline

• AAV OPTIRPE65 · Ophthalmology
  Gene therapy targeting RPE65

Phase 1 pipeline

• AAV - CNGB3 · Ophthalmology
  Gene therapy targeting the CNGB3 gene
• AAV RPE65 · Ophthalmology
  Gene therapy for RPE65-mediated inherited retinal dystrophy
• adeno-associated virus vector AAV- CNGA3

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• MeiraGTx UK II Ltd portfolio CI brief
• MeiraGTx UK II Ltd pipeline updates RSS